Cargando…

Successful Management of Graft Reinfection of HCV Genotype 2 in Living Donor Liver Transplantation from a Hepatitis B Core Antibody-Positive Donor with Sofosbuvir and Ribavirin

Direct-acting antivirals (DAAs) are relatively safe and highly effective for the eradication of hepatitis C virus (HCV) in liver transplant recipients. In this case study, we present a female with a graft reinfected with HCV genotype 2 who was treated with a combination of sofosbuvir and ribavirin a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sasaki, Reina, Kanda, Tatsuo, Ohtsuka, Masayuki, Yasui, Shin, Haga, Yuki, Nakamura, Masato, Yokoyama, Masayuki, Wu, Shuang, Nakamoto, Shingo, Arai, Makoto, Maruyama, Hitoshi, Miyazaki, Masaru, Yokosuka, Osamu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2016
Materias:	Single Case
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043295/ https://www.ncbi.nlm.nih.gov/pubmed/27721720 http://dx.doi.org/10.1159/000447423

Ejemplares similares

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report
por: Ohta, Yuki, et al.
Publicado: (2016)

Acute Liver Failure Occurring during the First Trimester of Pregnancy Successfully Treated with Living Donor Liver Transplantation
por: Kanogawa, Naoya, et al.
Publicado: (2013)

Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors
por: Kanda, Tatsuo, et al.
Publicado: (2017)

Drug-Induced Liver Injury Associated with Complementary and Alternative Medicines
por: Takahashi, Koji, et al.
Publicado: (2016)

Sustained Virologic Response at 24 Weeks after the End of Treatment Is a Better Predictor for Treatment Outcome in Real-World HCV-Infected Patients Treated by HCV NS3/4A Protease Inhibitors with Peginterferon plus Ribavirin
por: Kanda, Tatsuo, et al.
Publicado: (2016)

Successful Management of Acute Liver Failure Patients Waiting for Liver Transplantation by On-Line Hemodiafiltration with an Arteriovenous Fistula
por: Haga, Yuki, et al.
Publicado: (2016)

Effect of Hepatitis C Virus Genotype 1b Core and NS5A Mutations on Response to Peginterferon Plus Ribavirin Combination Therapy
por: Nakamoto, Shingo, et al.
Publicado: (2015)

An HCV‐positive recipient of an HCV‐positive donor liver successfully treated before and immediately after liver transplant with daclatasvir, sofosbuvir, and ribavirin
por: Poordad, Fred, et al.
Publicado: (2017)

Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan
por: Kanda, Tatsuo, et al.
Publicado: (2016)

Sustained Virological Response after 8-Week Treatment of Simeprevir with Peginterferon α-2a plus Ribavirin in a Japanese Female with Hepatitis C Virus Genotype 1b and IL28B Minor Genotype
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Efficacy and safety of sofosbuvir–velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial
por: Takehara, Tetsuo, et al.
Publicado: (2018)

IFNL4 ss469415590 Variant Is Associated with Treatment Response in Japanese HCV Genotype 1 Infected Individuals Treated with IFN-Including Regimens
por: Miyamura, Tatsuo, et al.
Publicado: (2014)

Pulmonary Embolism in a Donor of Living Donor Liver Transplantation
por: Onda, Shinji, et al.
Publicado: (2019)

Successful retreatment with sofosbuvir plus ledipasvir for cirrhotic patients with hepatitis C virus genotype 1b, who discontinued the prior treatment with asunaprevir plus daclatasvir: A case series and review of the literature
por: Haga, Yuki, et al.
Publicado: (2017)

Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin
por: Miyamura, Tatsuo, et al.
Publicado: (2012)

Alanine Aminotransferase Elevation during Peginterferon Alpha-2a or Alpha-2b plus Ribavirin Treatment
por: Nakamura, Masato, et al.
Publicado: (2013)

Association of IFNL3 Genotype with Hepatic Steatosis in Chronic Hepatitis C Patients Treated with Peginterferon and Ribavirin Combination Therapy
por: Nakamoto, Shingo, et al.
Publicado: (2017)

Recent Trend of Hepatitis E Virus Infection in Chiba Area, Japan: 3 of 5 Cases with Rheumatoid Arthritis
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Could Not Always Predict Early Cirrhosis in Non-Viral Liver Diseases
por: Haga, Yuki, et al.
Publicado: (2016)

Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus
por: Yada, Masayoshi, et al.
Publicado: (2018)

Efficacy and Safety of Sofosbuvir and Ribavirin in an Italian Cohort of HCV Genotype 2 Elderly Cirrhotic Patients
por: Smirne, Carlo, et al.
Publicado: (2022)

Peripheral blood correlates of virologic relapse after Sofosbuvir and Ribavirin treatment of Genotype-1 HCV infection
por: Orr, Cody, et al.
Publicado: (2020)

Sofosbuvir plus Ribavirin is effective for HCV elimination in people living with HIV from rural area of China
por: Chen, Liyu, et al.
Publicado: (2021)

Circulating microRNAs as predictors of response to sofosbuvir + daclatasvir + ribavirin in in HCV genotype-4 Egyptian patients
por: Hassuna, Noha Anwar, et al.
Publicado: (2022)

Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors
por: Chen, Ruoyang, et al.
Publicado: (2021)

No Regional Disparities in Sofosbuvir Plus Ribavirin Therapy for HCV Genotype 2 Infection in Tochigi Prefecture and Its Vicinity
por: Hirosawa, Takuya, et al.
Publicado: (2018)

Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study
por: Welzel, Tania M, et al.
Publicado: (2017)

No Correlation between PNPLA3 rs738409 Genotype and Fatty Liver and Hepatic Cirrhosis in Japanese Patients with HCV
por: Nakamura, Masato, et al.
Publicado: (2013)

Ledipasvir/sofosbuvir and ribavirin for the treatment of ribavirin-refractory persistent hepatitis E virus infection
por: Gallacher, Jennifer, et al.
Publicado: (2023)

Successful Eradication of Hepatitis C Virus by Interferon-Free Regimens in Two Patients with Advanced Liver Fibrosis following Kidney Transplantation
por: Sasaki, Reina, et al.
Publicado: (2016)

Renal Infarction during Anticoagulant Therapy after Living Donor Liver Transplantation
por: Onda, Shinji, et al.
Publicado: (2018)

Successful Treatment with Crushed Sofosbuvir/Velpatasvir of a Patient with Decompensated Cirrhosis C and Thrombocytopenia
por: Murayama, Aiko, et al.
Publicado: (2021)

Direct-acting Antivirals and Host-targeting Agents against the Hepatitis A Virus
por: Kanda, Tatsuo, et al.
Publicado: (2015)

MicroRNA-122 Inhibits the Production of Inflammatory Cytokines by Targeting the PKR Activator PACT in Human Hepatic Stellate Cells
por: Nakamura, Masato, et al.
Publicado: (2015)

Possible Involvement of Hepatitis B Virus Infection of Hepatocytes in the Attenuation of Apoptosis in Hepatic Stellate Cells
por: Sasaki, Reina, et al.
Publicado: (2016)

Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines
por: Haga, Yuki, et al.
Publicado: (2017)

HBV Core Protein Enhances Cytokine Production
por: Kanda, Tatsuo, et al.
Publicado: (2015)

Safety of Sofosbuvir and Ribavirin Combination Therapy in a Patient Who Developed Anemia due to Ribavirin
por: Suii, Hirokazu, et al.
Publicado: (2017)

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study
por: Sacco, Rodolfo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_328r19fsknkp654v11m5gg1muc